|
Aug 14
|
Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment
|
|
Aug 12
|
Scholar Rock’s Apitegromab Maintains Lean Mass In Phase 2 EMBRAZE Trial With Tirzepatide-Induced Weight Loss
|
|
Aug 6
|
Why Scholar Rock Stock Wilted on Wednesday
|
|
Aug 6
|
Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress
|
|
Jul 21
|
Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025
|
|
May 7
|
Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025
|
|
Apr 28
|
Why Scholar Rock Stock Took a Knock on Monday
|
|
Apr 28
|
Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth
|
|
Feb 14
|
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Feb 10
|
Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025
|
|
Jan 2
|
Scholar Rock to Present at the 43rd Annual J.P. Morgan Healthcare Conference
|